Norepinephrine Reuptake Inhibitor class drugs

4 results

  • atomoxetine

    (Atomoxetine)
    Aurobindo Pharma Limited
    Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients aged 6-18 and adults. They are part of a comprehensive treatment program that may include psychological and educational measures, and are not intended for patients with ADHD symptoms secondary to environmental factors or other psychiatric conditions.
    Medication Details
    Drug Interactions

  • atomoxetine

    (Atomoxetine)
    Rising Pharma Holdings, Inc.
    Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients (ages 6-18) and adults. It is part of a comprehensive treatment program, which may include other psychological, educational, and social interventions. It is not intended for symptoms due to environmental factors or primary psychiatric disorders.
    Medication Details
    Drug Interactions

  • atomoxetine

    (atomoxetine)
    Glenmark Pharmaceuticals Inc., USA
    Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients (ages 6-18) and adults. It is part of a comprehensive treatment program which may include psychological and educational measures, and is not intended for patients with symptoms due to environmental factors or other psychiatric disorders.
    Medication Details
    Drug Interactions

  • qelbree

    (viloxazine hydrochloride)
    Supernus Pharmaceuticals, Inc
    Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in individuals aged 6 years and older, including adults.
    Medication Details
    Drug Interactions